Lancet Respiratory Medicine

Article	Citations
Savolitinib in NSCLC: progress in the MET exon 14 journey	1157
US Senate committee investigates asthma inhaler prices	528
Concerns regarding a suggested long COVID paradigm – Authors' reply	425
Broad protection from SARS-CoV-2 variants without antigen matching	327
European Respiratory Society International Congress 2022	276
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	264
Opioids bring peace to patients with IPF cough	249
Video laryngoscopy is not the nemesis of direct laryngoscopy	246
Impact of Myanmar's earthquake on respiratory health	239
Predatory publishers appear in PubMed (and your inbox)	232
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	220
FLiRTing with danger as SARS-CoV-2 variants evolve	213
Thoracentesis: an old story and some new sources	207
Chronic obstructive pulmonary disease: 10 years of precision-guided success	205
Correction to Lancet Respir Med 2024; 12: 129–40	201
Interstitial lung disease: a decade of progress and hope	200
Australia bans engineered stone to prevent silicosis	200
The burden of tuberculosis in Libya	194
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	192
Rethinking the role of procalcitonin in suspected sepsis	191
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	189
Chronic respiratory diseases in Asia: time for action	185
Predicted bodyweight—a misleading metric for tidal volume titration?	185
Major gaps in childhood pneumonia research priorities remain	182
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	177

Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	172
Rituximab for connective tissue disease-associated interstitial lung disease	172
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	163
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	158
Long COVID: systemic inflammation and obesity as therapeutic targets	158
Concerns about PRISm	156
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	156
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	147
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	147
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	143
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, m	143
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	134
Association of SARS-CoV-2 infection and persistence with long COVID	134
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	132
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	132
Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial	131
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	128
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	127
Non-invasive respiratory supports and criteria for intubation in randomised trials of acute hypoxaemic respiratory failure: a systematic review and network meta-analysis	126
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	123
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	120
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	119
Claudio Castanos—leader in cystic fibrosis care in Argentina	114
Solid and semi-solid perspectives in thoracic surgery	113
Priorities for NICE in health and social care	113
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	113
Genetic associations and lung function in IPF: unexpected answers, persistent questions	112
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	112
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	111
Trump administration decimates worker health oversight	109
Extracorporeal cardiopulmonary resuscitation: not why, but how	109
Correction to Lancet Respir Med 2022; 10: 972–84	107
Correction to Lancet Respir Med 2021; 9: 1275–87	107
Correction to Lancet Respir Med 2025; 13: 244–55	106
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis	104
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	103
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	103
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	100
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	100
Chronic cough as a disease: implications for practice, research, and health care	99
Health effects from climate-driven events: lessons learnt	98
Choice overload for RSV prevention—how to form your opinion	97
Spirometry in female individuals – Authors' reply	97
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	96
Developments and priorities in bronchiectasis research	95
Pre-COPD: an evolving concept with practice potential	94
The Ramp to Nowhere: When hope slips through the cracks in care	93
Realignment of clinical research after the COVID-19 era	93
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	93
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	91

Tackling tuberculosis: what lies beneath the surface?	91
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	90
Underappreciated causes of obstructive lung disease	89
COP27 Climate Change Conference: urgent action needed for Africa and the world	89
COPD: a complex, multifactorial, but preventable disease?	88
Liberal or restrictive transfusion for VV ECMO	88
Clean air, climate targets, and respiratory health in Europe	88
Trouble with promoting lung cancer screening in never-smokers	88
Correction to Lancet Respir Med 2023; 11: 1064–74	86
Unveiling a hidden phenotype of early tuberculosis	86
Russell Winwood: “COPD Athlete” defying views on lung disease	81
Real-time subphenotyping in acute respiratory distress syndrome: a step towards precision medicine	79
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	79
Pulmonary hydatid disease in children: a neglected burden hidden in plain sight	76
Pooled testing for TB: revisiting a cost-saving innovation	73
Opioid use and sleep apnoea	72
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	71
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration	68
US lung cancer report suggests years of encouraging progress under threat from health agency cuts	67
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	67
Early-life respiratory syncytial virus disease and long-term respiratory health	66
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	66
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	66
Treating acute respiratory illness: the need to be proactive	65
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	65
The recent explosion in snortable energy powder consumption	65
Collateral caring	65
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	65
US EPA backs industry lawsuit to undo its own work on air pollution rule	64
Breathing barriers: bridging lung health, research, and awareness	63
Assessing the reversibility of bronchiectasis with deep learning	63
A benchmarking study and roadmap for sepsis: who dies from septic shock?	63
Wildfires in southern California: concerns for lung health	62
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	61
Society of Critical Care Medicine Critical Care Congress 2023	61
Correction to Lancet Respir Med 2022; published online Feb 25. https://doi.org/10.1016/S2213-2600(22)00045-5	61
E-cigarette company tactics in sports advertising	61
Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PR	59
COVID-19—an infectious disease in the top five causes of death in Australia	59
Combined SHP2 and KRASG12C inhibitor therapy in patients with non-small-cell lung cancer	59
Beyond the ventilator: rethinking daily evaluation of respiratory drive and effort	59
Managing tuberculosis before the onset of symptoms	58
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	58
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	57
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	57
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial	56
Pioneering a paradigm shift in asthma management: remission as a treatment goal	56
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	56
Trial emulation with observational data in cystic fibrosis	55
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial	55
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	55
Continuing ECMO with no possible transition to recovery or transplant	55
Home monitoring in interstitial lung diseases	55
NUTRIREA-3: where to next?	55
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	55
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	55
Tackling the global burden of lung disease through prevention and early diagnosis	54
Correction to Lancet Respir Med 2025; 13: 800–08	54
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	53
Common and rare variants and survival in idiopathic pulmonary fibrosis	53
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	53
Moving forward in IPF: lessons learned from clinical trials	52
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	50
Rise in group A streptococcal infections in England	48
EVEREST and the eosinophil paradox – Authors' reply	48
What is adequate preoxygenation? – Authors' reply	47
The importance of post-tuberculosis morbidity in high-income countries	47
Remission in chronic cough: an achievable target?	47
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	46
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	45
JCOG0802 and CALGB140503: the gap between trial design and clinical application	45
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	45
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	44
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	44
Non-invasive respiratory support improves outcomes in high-income countries	44
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	43
Perioperative lung expansion and pulmonary outcomes after abdominal surgery	42
European Lung Cancer Congress 2024	42
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	42
Reflections 5 years on from the approval of ETI therapy	42

General population-based lung function trajectories over the life course: an accelerated cohort study	42
Use of lung-cancer trends for global and public health priorities	41
Flavia Machado—a Latin American leader in sepsis	40
Stubble: the Farmer's Bane	40
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	39
Guidelines might help reduce the burden of asthma in African children	39
The upcoming influenza season and protection from vaccines	37
Lifting the veil on humour and anaesthetics	37
US Senate announces planned gun reforms after latest school shooting	37
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	36
Neomi Shah—cracking the conundrum of sleep disorders	36
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	36
Community-acquired pneumonia: the best candidates for clarithromycin	36
When evidence is not enough: making videolaryngoscopy the default for tracheal intubation	35
International guideline recommendations and eligibility criteria for home oxygen therapy	35
Surviving sepsis with multiple serious complications	34
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	34
ECMO: more than just a bridge over troubled waters?	34
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial	34
Correction to Lancet Respir Med 2024; 12: 544–55	34
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	34
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	33
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	33
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	32
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	32
Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlle	31
Management of prematurity-associated lung disease from infancy through to adulthood	31
Ventilation during surgery: moving away from one-size-fits-all	31
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	31
Fighting sepsis: still a long way to go	30
Oral corticosteroids for acute preschool wheeze	30
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	30
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study	30
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	30
How early should CFTR modulators be initiated to prevent structural cystic fibrosis lung disease?	30
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	29
Correction Lancet Respir Med 2022; 10: 937–48	29
Discussions on VT4COVID	29
Concerns regarding a suggested long COVID paradigm	29
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	29
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	29
The carbon footprint of inhaled medications in Australia	28
Correction to Lancet Respir Med 2025; 13: 318–26	28
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients	27
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	27
Lockdown as the mother of invention: disruptive technology in a disrupted time	27
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	27
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply	26
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents	26
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	26
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	25
Continued resuscitation at the scene versus early transport for refractory out-of-hospital cardiac arrest	25
Air pollution, climate change, and lung health in Europe	25
How Glasgow's 1957 tuberculosis screening programme could help countries today	24
Home-based monitoring in chronic respiratory diseases: in search of Panacea	24
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	24
Tuberculosis prevalence: beyond the tip of the iceberg	24
Neurofilament light chain in post-cardiac arrest prognostication: from signal to strategy	24
US EPA strengthens PM2·5 air pollution limits	24
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	23
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria	23
Remdesivir saves lives. Were 3 years needed to learn that?	23
Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX): a multicentre, randomised, sham-controlled trial	23
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial	23
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	23
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	22
Living with spinal muscular atrophy while working in critical care	22
European Respiratory Society International Congress 2024	22
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	22
Treatment strategy for EGFR mutated NSCLC	21
Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, rando	21
Chronic obstructive pulmonary disease: new therapies and old needs	21
Navigating uncertainty: asthma biologics during pregnancy	21
Opportunities and challenges of COPD tertiary prevention	21
What is next for BCG revaccination to prevent tuberculosis?	20
Add-on LAMA therapy in asthma: an underused strategy for exacerbation prevention	20
Phenotypes of idiopathic pulmonary arterial hypertension	20
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa	20
Tuberculosis, conflict, and displacement	20
Implementing endotoxin adsorption for septic shock into clinical practice	20
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	20
Can the positive findings from POD1UM-304 improve patient care worldwide?	19
Sedative medications: an avoidable cause of asthma and COPD exacerbations?	19
The future of paediatric acute respiratory distress syndrome	19
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials	19
The Wuhan lockdown	19
Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise	18
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study	18
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	18
Idiopathic inflammatory myopathies related lung disease in adults	18
Addressing the origins and health effects of small lungs	18
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study	18
D-dimer thresholds in pulmonary embolism: avoiding one-size-fits-all	18
European Lung Cancer Congress 2023	17
Mild hypothermia for expanded criteria kidney donors: balancing evidence and uncertainty	17